Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.
Kumar R, Jonnatan S, Sanin DE, Vakkala V, Kadam A, Kumar S, Dalrymple SL, Zhao L, Foley J, Holbert CE, Nwafor A, Kittane S, Penner E, Apostolova P, Warner S, Dang CV, Toska E, Thompson EA, Isaacs JT, De Marzo AM, Pearce EL, Stewart TM, Casero RA, Denmeade SR, Sena LA. Kumar R, et al. Among authors: toska e. medRxiv [Preprint]. 2024 Dec 13:2024.12.12.24318845. doi: 10.1101/2024.12.12.24318845. medRxiv. 2024. PMID: 39711733 Free PMC article. Preprint.
Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies.
Ditonno F, Pettenuzzo G, Montanaro F, De Bon L, Costantino S, Toska E, Malandra S, Cianflone F, Bianchi A, Porcaro AB, Cerruto MA, Veccia A, Bertolo R, Antonelli A. Ditonno F, et al. Among authors: toska e. Prostate Cancer Prostatic Dis. 2024 Oct 15. doi: 10.1038/s41391-024-00908-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39402370 Review.
Outcomes of da Vinci® versus Hugo RAS® radical prostatectomy: focus on postoperative course, pathological findings, and patients' health-related quality of life after 100 consecutive cases (the COMPAR-P prospective trial).
Antonelli A, Veccia A, Malandra S, Rizzetto R, Artoni F, Fracasso P, Fumanelli F, Palumbo I, Raiti A, Roggero L, Treccani LP, Vetro V, DE Marco V, Porcaro AB, Cerruto MA, Brunelli M, Bertolo R; Residency Program in Urology at the University of Verona. Antonelli A, et al. Minerva Urol Nephrol. 2024 Oct;76(5):596-605. doi: 10.23736/S2724-6051.24.05928-7. Minerva Urol Nephrol. 2024. PMID: 39320250 Clinical Trial.
Mutant ARID1A: igniting cancer immunotherapy.
Vokshi BH, Toska E. Vokshi BH, et al. Among authors: toska e. Trends Immunol. 2024 Aug;45(8):565-567. doi: 10.1016/j.it.2024.07.003. Epub 2024 Jul 26. Trends Immunol. 2024. PMID: 39068111 Review.
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, Diana P, Vuina K, de Bruin RAM, Surana U, Bardia A, Kumar AP. Glaviano A, et al. Among authors: toska e. Drug Resist Updat. 2024 Sep;76:101103. doi: 10.1016/j.drup.2024.101103. Epub 2024 Jun 25. Drug Resist Updat. 2024. PMID: 38943828 Free article. Review.
152 results